Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18894673 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | September 2024 | June 2025 | Abandon | 8 | 0 | 1 | No | No |
| 18739955 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18588987 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18588956 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | February 2024 | October 2024 | Abandon | 8 | 0 | 1 | No | No |
| 18588930 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18407334 | DETERGENT COMPOSITIONS COMPRISING BACTERIAL MANNANASES | January 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18505438 | METHODS AND SYSTEMS FOR THE CULTURE OF CELLS AT LIQUID-LIQUID INTERFACES | November 2023 | June 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18471478 | ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTION | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18350559 | AGRICULTURALLY BENEFICIAL MICROBES, MICROBIAL COMPOSITIONS, AND CONSORTIA | July 2023 | October 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18134722 | PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | April 2023 | September 2024 | Allow | 18 | 2 | 0 | No | No |
| 18295428 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS | April 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18295041 | Device and Method for the Sequestration of Atmospheric Carbon Dioxide | April 2023 | October 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18153974 | MEDIA FOR STEM CELL PROLIFERATION AND INDUCTION | January 2023 | October 2023 | Allow | 9 | 0 | 0 | No | No |
| 18151095 | SYSTEM AND METHOD FOR LIQUID FUEL PRODUCTION FROM CARBONACEOUS MATERIALS USING RECYCLED CONDITIONED SYNGAS | January 2023 | January 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18051969 | ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTION | November 2022 | September 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17935832 | Medium and Methods For The Storage of Red Blood Cells | September 2022 | November 2024 | Allow | 26 | 2 | 0 | No | No |
| 17743276 | METHOD FOR PRODUCTION OF A SOIL AMENDMENT | May 2022 | December 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17727425 | Composition and Method for Disrupting Tissue Material | April 2022 | June 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17660051 | ANTI-CANCER ONCOLYTIC VIRUS COMBINATION THERAPIES AND ELITE RESPONDER SELECTION PLATFORMS | April 2022 | April 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17712697 | SERUM-FREE CELL CULTURE MEDIUM | April 2022 | March 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17693500 | HUMAN FACILITATING CELLS | March 2022 | June 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17692579 | HERBAL COMPOSITION IN POWDER, PILL OR LIQUID FORM FOR SPEEDING UP FRACTURE HEALING AND BONE REGENERATION AND HERBAL FORMULATION IN POWDER, PILL OR LIQUID FORM CONTAINING THE SAME | March 2022 | November 2022 | Allow | 8 | 1 | 0 | No | No |
| 17687799 | USE OF ADHERENT STROMAL CELLS FOR ENHANCING HEMATOPOIESIS IN A SUBJECT IN NEED THEREOF | March 2022 | December 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17675502 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | February 2022 | February 2024 | Allow | 24 | 1 | 0 | No | No |
| 17636259 | GROWING PROGRAMMABLE ENZYME-FUNCTIONALIZED AND SENSE-AND-RESPONSE BACTERIAL CELLULOSE LIVING MATERIALS WITH ENGINEERED MICROBIAL CO-CULTURES | February 2022 | November 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17617290 | NON-TOXIC PROTEASE HAVING IMPROVED PRODUCTIVITY | December 2021 | June 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17511079 | MAINTENANCE OF DIFFERENTIATED CELLS WITH LAMININS | October 2021 | May 2025 | Allow | 43 | 4 | 0 | No | No |
| 17501775 | LYOPHILIZED COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | October 2021 | June 2025 | Allow | 44 | 5 | 0 | Yes | No |
| 17468765 | Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral Agent | September 2021 | December 2023 | Allow | 27 | 1 | 0 | No | No |
| 17396530 | APPARATUS AND METHOD FOR DETECTING CELLS OR PARTICLES IN A FLUID CONTAINER | August 2021 | December 2023 | Allow | 28 | 2 | 0 | No | No |
| 17389986 | USE OF LACTIC ACID BACTERIA FOR PREPARING FERMENTED FOOD PRODUCTS WITH INCREASED NATURAL SWEETNESS | July 2021 | December 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17370389 | SERUM-FREE CELL CULTURE MEDIUM | July 2021 | December 2023 | Allow | 29 | 4 | 0 | Yes | No |
| 17364868 | METHOD AND DEVICE FOR OPENING AN EXTERNAL LAYER STRUCTURE OF CELLS USING LASER | June 2021 | May 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17349061 | HERBAL COMPOSITION FOR REDUCING URIC ACID AND THE USE IN REDUCING URIC ACID, BODY FAT, AND BLOOD GLUCOSE THEREOF | June 2021 | March 2025 | Allow | 45 | 3 | 0 | No | No |
| 17307821 | SYSTEM AND METHODS FOR IDENTIFYING CANCER CELL LINES HAVING ANTI-GROWTH ACTIVITY AGAINST OTHER CANCER CELL LINES | May 2021 | November 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17276274 | INSECT-PATHOGENIC FUNGUS, SPORES, COMPOSITION AND USE OF SAME | March 2021 | June 2025 | Allow | 51 | 2 | 0 | No | No |
| 17275940 | ANIMAL FEED COMPOSITIONS AND USES THEREOF | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17178171 | Reversible method for sustainable human cognitive enhancement | February 2021 | March 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17173327 | OPTICAL BIO-SENSING DEVICE FOR BIO-MATERIAL ANALYSIS USING UPCONVERSION NANOPARTICLES, AND BIO-MATERIAL QUANTITATIVE ANALYSIS USING THE SAME | February 2021 | March 2024 | Allow | 37 | 1 | 0 | No | No |
| 17173113 | Methods for sustainable human cognitive enhancement | February 2021 | March 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17265527 | CELL-FREE PROTEIN SYNTHESIS METHOD | February 2021 | October 2022 | Abandon | 20 | 2 | 0 | Yes | No |
| 17165192 | NOVEL VIOLAXANTHIN-OVERPRODUCING STRAIN OF CHLORELLA VULGARIS AND THE METHOD FOR PRODUCING VIOLAXANTHIN USING THE SAME | February 2021 | April 2023 | Allow | 27 | 1 | 0 | No | No |
| 17264096 | MEANS AND METHODS FOR CLEAVAGE OF ZEARALENONE | January 2021 | March 2025 | Allow | 50 | 1 | 1 | No | No |
| 17152074 | IMMOBILIZED PROTEINS AND USE THEREOF | January 2021 | October 2023 | Abandon | 33 | 4 | 0 | No | Yes |
| 17258783 | SYSTEM AND METHOD FOR MODULATING STRESS GRANULE ASSEMBLY | January 2021 | September 2024 | Allow | 44 | 2 | 1 | No | No |
| 17143755 | ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTION | January 2021 | October 2022 | Allow | 21 | 0 | 1 | No | No |
| 17258084 | PDE3B VARIANTS | January 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17256210 | Systems and methods for measuring liver enzyme levels in blood | December 2020 | December 2024 | Allow | 47 | 2 | 0 | Yes | Yes |
| 17255056 | ANTI-INFLUENZA VIRUS AGENT FOR SUPPRESSING AGGRAVATION OF INFLUENZA | December 2020 | October 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17253845 | Nucleic Acid Binding Domains and Methods of Use Thereof | December 2020 | November 2024 | Allow | 47 | 2 | 0 | No | No |
| 17116978 | ENZYME FORMULATION AND METHOD FOR DEGRADATION | December 2020 | May 2025 | Abandon | 53 | 3 | 0 | No | No |
| 17105925 | MULTIPARTITE LUCIFERASE PEPTIDES AND POLYPEPTIDES | November 2020 | October 2024 | Allow | 47 | 2 | 1 | No | No |
| 17105438 | FERMENTATION PRODUCTION PROCESS OF PAECILOMYCES HEPIALIS CS-4 | November 2020 | March 2024 | Abandon | 40 | 2 | 0 | No | No |
| 16950464 | COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS | November 2020 | July 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17096787 | CELL POTENCY ASSAY FOR THERAPEUTIC POTENTIAL | November 2020 | September 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17063412 | OPTICAL-QUALITY SURFACE THAT IMPARTS SPATIAL CONTROL OF MACROPHAGE FUSION | October 2020 | December 2022 | Allow | 26 | 1 | 0 | No | No |
| 17012810 | BACTERIA FOR DEGRADING ETHYLENE OXIDE AND APPLICATIONS THEREOF | September 2020 | September 2021 | Allow | 13 | 2 | 0 | Yes | No |
| 17013424 | NUTRITIONAL SUPPLEMENTS AND METHODS OF NUTRITIONAL SUPPLEMENTATION AFFECTING MICROBIOME METABOLISM | September 2020 | May 2025 | Abandon | 56 | 4 | 0 | No | No |
| 16994356 | METHODS FOR TREATING DISEASE ASSOCIATED WITH SENESCENCE | August 2020 | October 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16942569 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | July 2020 | January 2025 | Abandon | 54 | 2 | 0 | No | No |
| 16961525 | SOLUBLE ALPHA-KLOTHO PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOF | July 2020 | October 2024 | Allow | 51 | 1 | 1 | No | No |
| 16958862 | METHODS AND SYSTEMS FOR THE CULTURE OF CELLS AT LIQUID-LIQUID INTERFACES | June 2020 | November 2023 | Abandon | 41 | 2 | 0 | No | No |
| 16955441 | EXTRACELLULAR MATRIX AND ITS USE FOR REGULATING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS | June 2020 | August 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16900970 | METHODS AND COMPOSITIONS FOR GENERATING EPICARDIUM CELLS | June 2020 | July 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16890050 | Microscopy for Rapid Antibiotic Susceptibility Test Using Membrane Fluorescence Staining and Spectral Intensity Ratio | June 2020 | November 2023 | Abandon | 41 | 2 | 0 | No | No |
| 16885999 | ROBUST DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS INTO ENDOTHELIAL CELLS USING TRANSCRIPTION FACTOR ETV2 | May 2020 | October 2024 | Abandon | 53 | 2 | 1 | No | Yes |
| 16767357 | HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME | May 2020 | January 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16872061 | HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPY | May 2020 | March 2024 | Abandon | 46 | 2 | 1 | No | No |
| 16761313 | DEVICE AND METHOD FOR THE SEQUESTRATION OF ATMOSPHERIC CARBON DIOXIDE | May 2020 | April 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16861171 | BIOLOGICAL TISSUE FOR SURGICAL IMPLANTATION | April 2020 | December 2024 | Abandon | 55 | 5 | 0 | No | No |
| 16814892 | SYSTEM AND METHOD FOR LIQUID FUEL PRODUCTION FROM CARBONACEOUS MATERIALS USING RECYCLED CONDITIONED SYNGAS | March 2020 | September 2022 | Allow | 30 | 3 | 1 | Yes | No |
| 16644490 | WASTE EVACUATION APPARATUS FOR AN AUTOMATED SPECIMEN PREPARATION SYSTEM | March 2020 | August 2023 | Allow | 41 | 1 | 0 | No | No |
| 16782372 | CRYOPROTECTANTS FOR FREEZE DRYING OF LACTIC ACID BACTERIA | February 2020 | December 2022 | Allow | 34 | 1 | 0 | No | No |
| 16634140 | FUNCTIONAL CORTICAL ORGANOIDS, METHODS OF MAKING, AND USES THEREOF | January 2020 | July 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16632229 | METHOD AND KIT FOR SINGLE CELL PROTEIN EXPRESSION PROFILING OF FLOORPLATE MESENCEPHALIC DOPAMINERGIC PROGENITOR CELLS | January 2020 | January 2024 | Allow | 48 | 2 | 0 | Yes | Yes |
| 16742695 | SERUM-FREE CELL CULTURE MEDIUM | January 2020 | January 2022 | Allow | 24 | 3 | 1 | Yes | No |
| 16723661 | Method for removal of harmful sulphurous compounds from gas mixtures | December 2019 | May 2023 | Allow | 41 | 2 | 0 | No | No |
| 16712379 | Implant for Injured Nerve Tissue Prosthetics, Method of Surgical Treatment for Injured Nerve Tissue and Use of Porous Polytetrafluorethylene | December 2019 | January 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16705966 | METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANS | December 2019 | June 2024 | Allow | 54 | 3 | 1 | No | No |
| 16618040 | PURSLANE PROCESSED MATERIAL, METHOD FOR PRODUCING PURSLANE PROCESSED MATERIAL, SUPPLEMENT, MEDICINE, INTESTINAL MUCOSA PROTECTIVE AGENT, AND INTESTINAL REGULATOR | November 2019 | November 2022 | Abandon | 35 | 0 | 1 | No | No |
| 16692198 | METHOD OF MANUFACTURING A CULTURE SUPPORT HAVING IMPROVED CELL ADHESIVENESS AND MOBILITY | November 2019 | January 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16686437 | COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMS | November 2019 | June 2021 | Abandon | 19 | 2 | 0 | Yes | No |
| 16667981 | WHOLE BLOOD VOLUME ANALYZER | October 2019 | June 2024 | Abandon | 55 | 2 | 1 | Yes | No |
| 16657501 | Nasal Compositions and Method of Use Thereof | October 2019 | October 2022 | Allow | 36 | 2 | 0 | Yes | No |
| 16655506 | PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | October 2019 | February 2023 | Allow | 40 | 2 | 0 | Yes | No |
| 16604633 | PRINTED TEST STRIPS TO DETERMINE GLUCOSE CONCENTRATION IN AQUEOUS LIQUIDS | October 2019 | January 2024 | Allow | 51 | 4 | 0 | Yes | Yes |
| 16603213 | STRAIN IN MICROBACTERIUM AND METHOD FOR PRODUCING PSICOSE USING SAME | October 2019 | August 2023 | Allow | 47 | 3 | 0 | No | No |
| 16500603 | DETERGENT COMPOSITIONS COMPRISING BACTERIAL MANNANASES | October 2019 | December 2023 | Allow | 50 | 4 | 1 | Yes | No |
| 16583502 | Methods for Culturing Cells in an Alternating Ionic Magnetic Resonance (AIMR) Multiple-Chambered Culture Apparatus | September 2019 | October 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16579195 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | September 2019 | April 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16494728 | METHOD FOR IRRADIATING MAMMALIAN CELLS WITH ELECTRON BEAMS AND/OR X-RAYS | September 2019 | June 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16492972 | MICROBIOLOGICAL TESTING DEVICE, METHOD FOR PROVISION AND USE OF SUCH A DEVICE | September 2019 | December 2022 | Allow | 39 | 2 | 0 | No | No |
| 16490282 | METHOD FOR THE ENZYMATIC SACCHARIFICATION OF A POLYSACCHARIDE | August 2019 | December 2021 | Abandon | 27 | 2 | 0 | No | No |
| 16550720 | METHOD TO INDUCE SPORE GERMINATION IN FUNGI | August 2019 | January 2023 | Allow | 40 | 2 | 0 | No | No |
| 16546424 | COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMS | August 2019 | July 2020 | Allow | 11 | 1 | 0 | No | No |
| 16512836 | COMPOSITIONS AND METHODS FOR THE DETECTION OF ZINC | July 2019 | May 2022 | Allow | 34 | 1 | 0 | Yes | No |
| 16501931 | Method and apparatus to collect, fractionate, and classify airborne particles within specified volumetric regions | July 2019 | March 2021 | Abandon | 20 | 2 | 0 | Yes | No |
| 16446971 | METHODS OF TRANSFECTION USING SONOPORATION | June 2019 | September 2023 | Allow | 51 | 4 | 0 | Yes | No |
| 16434131 | METHOD FOR ASSAYING BIOLOGICAL SAMPLE ON MICROFABRICATED CHIP | June 2019 | January 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16406862 | BIOLOGICAL TISSUE FOR SURGICAL IMPLANTATION | May 2019 | November 2023 | Abandon | 55 | 4 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CLARKE, TRENT R.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CLARKE, TRENT R works in Art Unit 1651 and has examined 414 patent applications in our dataset. With an allowance rate of 37.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CLARKE, TRENT R's allowance rate of 37.7% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CLARKE, TRENT R receive 2.76 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CLARKE, TRENT R is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.9% benefit to allowance rate for applications examined by CLARKE, TRENT R. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.2% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 48.3% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 68.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.